CFO SpotlightsCareers of chief financial officers, from the filings. Records as of October 28, 2026
  1. CFO Spotlights
  2. Profiles
  3. Jason Robins

Profile

Jason Robins

Chief Financial Officer, Ocular Therapeutix, Inc.

In the seat. First published here October 28, 2026; built from records as of October 28, 2026.

Jason Robins has been Chief Financial Officer of Ocular Therapeutix, Inc. since June 10, 2026, according to the company's filing of June 12, 2026.2

The filing gives Jason Robins's previous role as interim Chief Financial Officer at OCULAR THERAPEUTIX, INC.2 Jason Robins already worked at Ocular Therapeutix, Inc. when appointed, so the record counts the move as an internal promotion.2

Seats

The seat in the record

CompanyTitle as filedStandingFilings
Ocular Therapeutix, Inc. (OCUL)
Pharmaceutical Preparations
Chief Financial OfficerIn the seat2

Company names link to the company's page in the record at CFO Tribune, which holds the seat history.

The record

Filing by filing, latest first

  1. June 10, 2026effective

    Ocular Therapeutix, Inc. appointed Jason Robins as Chief Financial Officer, effective June 10, 2026.

    On June 10, 2026, the Board appointed Jason Robins, the Company’s interim Chief Financial Officer, to serve as the Chief Financial Officer.

    [2] Filing by Ocular Therapeutix, Inc., filed with the SEC on June 12, 2026. Read the filing. The record at CFO Tribune.

  2. February 5, 202610-K filed

    Jason Robins signed the annual report of Ocular Therapeutix, Inc. on Form 10-K as Interim Chief Financial Officer (Principal Financial and Accounting Officer), filed February 5, 2026.

    /s/ Jason Robins Jason Robins Interim Chief Financial Officer (Principal Financial and Accounting Officer)

    [1] Annual report on Form 10-K by Ocular Therapeutix, Inc., filed with the SEC on February 5, 2026. Read the filing. The record at CFO Tribune.

Sources

Sources

  1. Annual report on Form 10-K, Ocular Therapeutix, Inc.. U.S. Securities and Exchange Commission, EDGAR, filed February 5, 2026. sec.gov; record.
  2. Current report filed with the SEC, Ocular Therapeutix, Inc.. U.S. Securities and Exchange Commission, EDGAR, filed June 12, 2026. sec.gov; record.

Corrections and removal

If a line here is wrong, or Jason Robins wants this profile taken down, write to corrections@cfospotlights.com. Corrections are made on the page with a dated note; removal requests are answered within 72 hours. The underlying filings stay public at the SEC.